PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Completed
Phase 4 ResultsSummary of Purpose
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 22 April 2014.
1 Aug 2003 | 9 Sep 2005 | 1 Apr 2008 | Unavailable | 1 Apr 2014 | 6 Feb 2009 |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Double-Blind
- Purpose: Prevention
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
-
Beth Gervers Investigator Relations Patient Recruitment Specialist Kendle International Phone: 614-865-0473
hans.diener@uni-duisburg-essen.de
View Trial Locations
Recruitment
- Enrollment: 20,332
- Gender: Both
- Minimum Age: 50 Years
- Accepts Healthy Volunteers: No
- 675 locations, 36 countries
Principal Investigator
- Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals